Meylan Françoise, Davidson Todd S, Kahle Erin, Kinder Michelle, Acharya Krishika, Jankovic Dragana, Bundoc Virgilio, Hodges Marcus, Shevach Ethan M, Keane-Myers Andrea, Wang Eddie C Y, Siegel Richard M
Immunoregulation Unit, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892.
Immunity. 2008 Jul 18;29(1):79-89. doi: 10.1016/j.immuni.2008.04.021. Epub 2008 Jun 19.
DR3 (TRAMP, LARD, WSL-1, TNFRSF25) is a death-domain-containing tumor necrosis factor (TNF)-family receptor primarily expressed on T cells. TL1A, the TNF-family ligand for DR3, can costimulate T cells, but the physiological function of TL1A-DR3 interactions in immune responses is not known. Using DR3-deficient mice, we identified DR3 as the receptor responsible for TL1A-induced T cell costimulation and dendritic cells as the likely source for TL1A during T cell activation. Despite its role in costimulation, DR3 was not required for in vivo T cell priming, for polarization into T helper 1 (Th1), Th2, or Th17 effector cell subtypes, or for effective control of infection with Toxoplasma gondii. Instead, DR3 expression was required on T cells for immunopathology, local T cell accumulation, and cytokine production in Experimental Autoimmune Encephalomyelitis (EAE) and allergic lung inflammation, disease models that depend on distinct effector T cell subsets. DR3 could be an attractive therapeutic target for T cell-mediated autoimmune and allergic diseases.
DR3(TRAMP、LARD、WSL-1、TNFRSF25)是一种含死亡结构域的肿瘤坏死因子(TNF)家族受体,主要在T细胞上表达。TL1A是DR3的TNF家族配体,可共刺激T细胞,但TL1A-DR3相互作用在免疫反应中的生理功能尚不清楚。利用DR3缺陷小鼠,我们确定DR3是负责TL1A诱导的T细胞共刺激的受体,树突状细胞是T细胞激活过程中TL1A的可能来源。尽管DR3在共刺激中起作用,但体内T细胞致敏、分化为辅助性T细胞1(Th1)、Th2或Th17效应细胞亚型或有效控制弓形虫感染并不需要DR3。相反,在实验性自身免疫性脑脊髓炎(EAE)和过敏性肺部炎症(依赖于不同效应T细胞亚群的疾病模型)中,T细胞上的DR3表达对于免疫病理学、局部T细胞积聚和细胞因子产生是必需的。DR3可能是T细胞介导的自身免疫性疾病和过敏性疾病的一个有吸引力的治疗靶点。